• Loading metrics

A Scientometric Evaluation of the Chagas Disease Implementation Research Programme of the PAHO and TDR

  • Ana Laura Carbajal-de-la-Fuente,

    Affiliations Leishmaniasis Transmitters Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil, Laboratory of Eco-Epidemiology, Department of Ecology, Genetics and Evolution, (IEGEBA-CONICET) University of Buenos Aires, Buenos Aires, Argentina

  • Zaida E. Yadón

    Affiliation Communicable Diseases Unit, Health Surveillance, Disease Prevention and Control, Pan American Health Organization, Washington, D.C., United States of America

A Scientometric Evaluation of the Chagas Disease Implementation Research Programme of the PAHO and TDR

  • Ana Laura Carbajal-de-la-Fuente, 
  • Zaida E. Yadón


The Special Programme for Research and Training in Tropical Diseases (TDR) is an independent global programme of scientific collaboration cosponsored by the United Nations Children's Fund, the United Nations Development Program, the World Bank, and the World Health Organization. TDR's strategy is based on stewardship for research on infectious diseases of poverty, empowerment of endemic countries, research on neglected priority needs, and the promotion of scientific collaboration influencing global efforts to combat major tropical diseases. In 2001, in view of the achievements obtained in the reduction of transmission of Chagas disease through the Southern Cone Initiative and the improvement in Chagas disease control activities in some countries of the Andean and the Central American Initiatives, TDR transferred the Chagas Disease Implementation Research Programme (CIRP) to the Communicable Diseases Unit of the Pan American Health Organization (CD/PAHO).

This paper presents a scientometric evaluation of the 73 projects from 18 Latin American and European countries that were granted by CIRP/PAHO/TDR between 1997 and 2007. We analyzed all final reports of the funded projects and scientific publications, technical reports, and human resource training activities derived from them. Results about the number of projects funded, countries and institutions involved, gender analysis, number of published papers in indexed scientific journals, main topics funded, patents inscribed, and triatomine species studied are presented and discussed.

The results indicate that CIRP/PAHO/TDR initiative has contributed significantly, over the 1997–2007 period, to Chagas disease knowledge as well as to the individual and institutional-building capacity.


Chagas disease or American trypanosomiasis is caused by the protozoan Trypanosoma cruzi (Chagas, 1909) and transmitted to humans by a group of hemipteran insects belonging to the family Reduviidae, subfamily Triatominae [1]. The main mode of transmission in endemic areas is vectorial, by domestic, peridomestic, or sylvatic triatomines. The disease can also be transmitted by the congenital and oral routes, blood transfusion, organ transplantation, and laboratory accidents [2]. Currently, Chagas disease is considered a serious health problem in Latin America, with 9–10 million people infected [3]. It extends from the southern United States to southern Argentina and Chile [4], although it has been shown [5] that migration from endemic American countries to nonendemic countries makes Chagas disease a global health problem.

In 1984, it was estimated that over 100 million people in Latin America were at risk and that 24 million were already infected with T. cruzi [6]. Great progress has been made in its prevention and control in Latin America since the 90 s. Transmission has been interrupted in territories of the Southern Cone, Central American, Andean, and Amazonian Intergovernmental Initiatives led by the Pan American Health Organization (PAHO) [3]. These initiatives have led to substantial reductions in vectorial and transfusional transmission, decreasing the number of infected people from 16–18 million in the 90 s to 9–10 million currently [2], [4]. These advances and the interruption of T. cruzi transmission in many endemic countries have been possible because of the strong commitment of the endemic Member States, the strength of their national research and control organizations, and the support from many international partners [4], including Japan International Cooperation Agency (JICA), Canadian International Development Agency (CIDA), European Community-Seventh Framework Programme (EC-FP7), European Community-Latin American Network for Research on the Biology and Control of Triatominae (ECLAT), World Vision (WV), CARE International (CI), Médecins Sans Frontières (MSF), and the Special Programme for Research and Training in Tropical Diseases (TDR), among others [7][9].

Chagas disease research and control programmes are included in both the portfolios of the Communicable Diseases Unit/PAHO (CD/PAHO) and TDR. TDR is an independent global programme fostering scientific collaboration [10] that was established in 1975 to address the need for new and improved tools for disease control, and for strengthening the research capacity of endemic countries [11].

In 2001, in view of the achievements obtained in the reduction of the transmission of T. cruzi in the Southern Cone and the improvement of vector control activities in some countries of the Andean and the Central American Initiatives, TDR decided to transfer CIRP/PAHO/TDR to CD/PAHO [12], [13]. As a result, CD/PAHO also received the responsibility of managing the ongoing projects approved by TDR from 1997 to 2001. The first PAHO call for proposals was in 2002. One and a half million dollars to support research, training activities, and managerial issues were allotted for the 2002–2008 period.

To ensure that all research supported by CIRP/PAHO/TDR was conducted to the highest scientific level, a peer-review process was established, led by a multidisciplinary, multicountry, and gender-balanced Steering Committee (SC).

The evaluation of results achieved by a research programme is essential for formulating, reviewing, and improving institutional research policies aimed at ensuring the appropriate use of financial, human, and material resources and to promote strengthening and growth of an institution [14], [15]. In order to evaluate the research impact of CIRP/PAHO/TDR, we performed a scientometric analysis of its scientific and capacity-building achievements for the 1997–2007 period.

Material and Methods

The relevant projects for this analysis were identified through a database developed by PAHO that included information about investigators, home institutions, and key data from new, progress, renewal, and final scientific reports to TDR. In addition, relevant data used for the scientometric analysis were retrieved from the following specific sources:

1. Scientific Reports

Applicable data were extracted from the projects' scientific reports approved by the TDR Task Force from 1997 to 2001 and by the SC of CIRP/PAHO/TDR from 2002 to 2007. The scientific reports contained the main scientific contributions, publications, training, and patents derived from the research projects for the reporting period.

2. Publications Databases

Two databases were searched for the scientific production on Chagas disease research for the 1997–2010 period: PubMed ( and LILACS (

We searched for articles published in English, Portuguese, and Spanish that presented results of studies granted by CIRP/PAHO/TDR. The search terms used were the principal investigator (PI) name and the keywords related to the research subject. The number of citations of each article was obtained from a search in the Web of Knowledge databases. The five-year impact factor and the ISSN of each scientific journal were extracted from the Journal Citation Reports of the Web of Knowledge.

We also searched PubMed using the term "triatom*" in order to determine the ratio of publications derived from projects granted by CIRP/PAHO/TDR to the overall Chagas disease scientific production.

3. In-Depth Survey

Each PI filled a structured questionnaire to provide additional information on the publications (articles published in scientific journals, meetings proceedings, books, or book chapters; abstracts or expanded meetings abstracts; and texts in newspapers or magazines) related to the projects granted by the CIRP/PAHO/TDR. The questionnaire included additional questions about technical assistance (technical consultations and reports for governmental health authorities), extension activities (community workshops or other activities involving schools, communities, or health agencies, dissemination materials such as promotional materials, booklets, CDs/DVDs, radio and TV programmes, websites, etc.), and individual and institutional capacity building (graduation, specialization, Master and Ph.D. degrees, postdoctoral fellowships, and capacity-building or training activities).


1. Scientific Reports Analysis

A total of 73 projects were included in the present study: 16 projects transferred by TDR to CD/PAHO and funded between 1997 and 1999; 14 new projects funded in 2000–2001; and 43 projects funded between 2002 and 2007 (13 in 2002; ten in 2003; 12 in 2005; four in 2006; and four in 2007).

The 73 projects were coordinated by 58 PIs from 18 Latin American and European countries (Figure 1). The highest number of projects carried out by one single PI was five. PIs of 59% (n=43) of the projects were male, and 41% (n=30) were female. Six countries (Argentina, Mexico, Colombia, Ecuador, Brazil, and France) had both male and female PIs, four (Guatemala, Paraguay, Venezuela, and Uruguay) had only female PIs, and eight (Bolivia, Costa Rica, El Salvador, United Kingdom, Honduras, Panama, Peru, and Spain) had only male PIs.

Figure 1. Projects funded and proportion of published articles in indexed scientific journals by countries, CIRP/PAHO/TDR (1997–2007).

The majority of the institutions involved (78%) were located in developing countries. However, notable asymmetry in the number of funded projects per country was noted, with 46% of the projects concentrated in 22% of the participating countries. Argentina had the highest number of PIs granted (n=13), followed by Colombia (n=8), and Brazil (n=7). Argentina also had the highest number of papers published in indexed scientific journals (n=39), followed by Brazil (n=23), and France (n=22) (Figure 1). Universities obtained the highest number of granted projects (47%; n=34), followed by governmental health institutions (34%; n=25), research institutions (16%; n=12), and nongovernmental organizations (3%; n=2).

The main topics addressed by the funded projects included the origin of reinfestation; vector resistance to insecticides and the establishment of a Latin American network for studies on vector control; chemical control (e.g., substances as baits for trapping); cost-reduction/cost-effectiveness of insecticide interventions for control; risk maps and entomological surveillance; habitat suitability predictions; influence of sylvatic and peridomestic triatomines in domestic transmission; genetic and phenetic markers; population structure; primers design; validation of new criteria of cure; seroprevalence studies in children, blood banks, and general population; transmission mechanisms of T. cruzi; nonconventional flow-cytometric approaches; and a virtual atlas of Mexican triatomines. A total of 59 projects involved at least one vector in their studies, and the main triatomine species studied are shown in Figure 2.

Figure 2. Species of triatomines studied by projects funded by CIRP/PAHO/TDR, 1997–2007 period.

Legends: Tdi=Triatoma dimidiata; Tin=T. infestans; Rpr=Rhodnius prolixus; Rpa=R. pallescens; Pme=Panstrongylus megistus; Tps=T. pseudomaculata; Rro=R. robustus; Rpi=R. pictipes; Tso=T. sordida. Other species with one project funded: T. vitticeps, T. maculata, T. longipennis, P. geniculatus, R. pictipes, R. ecuadoriensis, and R. colombiensis.

2. Publication Databases Search

The CIRP/PAHO/TDR projects yielded 126 scientific articles and five book chapters, totaling 131 contributions published from 1997 to 2010. The average number of papers per year was one from 1997 to 1999 (n=3) and 11 from 2000 to 2010 (n=123). The highest and the lowest numbers of articles produced by a single project were 17 and one, respectively. The average time from the beginning of a project until the publication of the first related article was 3.4 years (range: one to eight years). The number of authors per article varied from one to 14, with an average of five coauthors per paper.

Of the 126 scientific articles, 120 were published by 31 PIs in 31 indexed journals of a total of 37, with an average five-year impact factor of 2.24 (Table 1). According to the of the Web of Knowledge databases, 84 of these 120 articles were cited in other articles, with an average of 38.3 citations (range: three to 125) per paper. The majority of the papers were written in English (n=112; 88.9%), followed by Spanish (n=8; 6.3%), and Portuguese (n=6; 4.8%). No scientific production was related to 31 CIRP/PAHO/TDR-funded projects (42.5%) involving 27 PIs. A summary of the results is shown in Table 2.

Table 1. Number of scientific articles derived from proposals to CIRP/PAHO/TDR, 1997–2007.

Table 2. Summary of main results for the projects funded by CIRP/PAHO/TDR about Chagas disease, 1997–2007.

The CIRP/PAHO/TDR projects yielded a mean of 1.8 scientific publications per project. Seventy-four (58.7%) of the scientific articles were coauthored by authors from different countries. The interaction among researchers was not high; 16 PIs of the 73 granted projects have some degree of synergetic collaboration.

A total of 1,487 papers were retrieved searching PubMed using the term "triatom*." Of them, 915 (61.5%) were related to the research priorities of the CIRP/PAHO/TDR programme [13]. With this same search criterion, we retrieved a total of 117 papers derived from projects granted by CIRP/PAHO/TDR, accounting for 12.8% (117/915) of the total scientific publications for the study period. An increase in the number of published articles by year was observed, excepting the 2002–2004 period (Figure 3). The main language was English (n=779), followed by Portuguese (n=79), Spanish (n=55), and French (n=2); 68.5% (n=627) of the published articles were concentrated in 19 journals, with Memorias do Instituto Oswaldo Cruz having the most published articles (n=190) (Table 3).

Figure 3. Number of studies identified and retrieved from PubMed using the parameter "triatom*," 1997–2010 period.

Table 3. Journals with ten or more published papers about Chagas disease recorded in PubMed using the search term "triatom*."

Table S1 shows examples of studies funded by CIRP/PAHO/TDR summarizing their main result and their impact in Chagas control practice.

3. In-Depth Survey

Forty-seven of the 58 PIs could be contacted. Among them, 30 PIs (51.7%) of 41 projects (56%) (Figure 4) completed and returned the questionnaires.

Figure 4. Flow diagram of the "in-depth survey" to Principal Investigators. CIRP/TDR/PAHO, 1997–2007 period.

The analysis of the questionnaires indicated that, on average, the scientific production per project was: 3.1 meeting abstracts (n=125), 2.7 graduated and post-graduate students (n=107), 0.4 technical reports (n=17), and 0.7 extension activities (n=27). In one single project, 750 health technicians were trained for carrying out entomo-epidemiological surveillance with the participation of the community. In addition, two patents were submitted related to chemical substances as baits for trapping triatomines: patent N° 012349/2003 in Brazil (National Institute of Industrial Propriety) by M. G. Lorenzo et al. and patent N° P000104304 in Argentina by A. Fontán et al.

CIRP/PAHO/TDR have organized and funded a series of training courses, including: a) Geographic Information Systems, spatial analysis and vector-borne diseases, with emphasis on Chagas disease (two courses with participants from ten countries of the Region); b) sampling and detection of sylvatic triatomines (two subregional courses, one in Bolivia and one in Guatemala with the participation of researchers and programme entomologists from South American countries and Central American countries and Mexico, respectively); c) evaluation of the cost-effectiveness of Chagas disease control interventions (two subregional courses, in Guatemala and Buenos Aires, respectively). In addition, the programme supported the organization of two meetings and the publication of their respective reports: a) decentralization and management of communicable diseases control in Latin America ( and b) Scientific Working Group on Chagas Disease ( (data not shown).


A huge body of scientific evidence has been gathered since the discovery of Chagas disease in 1909. Research has played an important role in the history of the control of Chagas disease, allowing a decrease of vectorial and transfusional transmission, and an interruption of T. cruzi transmission in some areas of the Region of the Americas [7], as well as the recognition of the limitations of interventions in some other areas [16]. Some of the research breakthroughs and control milestones were summarized in 1999 [7] and in a series of papers published during the celebration of the 100th anniversary of the discovery of the disease [1], [2], [17].

International organizations such as PAHO/WHO, JICA, CIDA, MSF, WV, CI, DNDi, EC-FP7 Programme, and ECLAT, among others, have played an important role in accompanying the Chagas control initiatives in the Region of the Americas, as well as in supporting key research for the control and interruption of transmission in many countries of the Region. CIRP/PAHO/TDR has been one of many initiatives supporting research and capacity building in institutions of endemic countries that have permitted the acquisition of knowledge that contributed to the generation of evidence for vector control of Chagas disease [18][21], treatment of chronic Chagas disease [22], [23], and standardization and validation of diagnostic techniques [24][26], among others key research priorities.

During this period, the programme has supported 73 research projects on issues identified as research needs for Chagas disease control; they were carried out in endemic countries by researchers that in their majority were working in institutions located in these countries. These projects yielded 126 scientific articles published in peer-reviewed journals with a mean of 1.8 scientific publications per project. Most of the scientific publications originated from the Southern Cone countries, with Argentina and Brazil publishing, as expected, the highest number since they are countries with a high research production [27], [28].

The main language of publication was English, followed by Portuguese and Spanish, the official languages of most endemic countries. Similar results were obtained by others authors using search terms such as "Chagas disease" or "Trypanosoma cruzi" [27]. Our findings indicate that 70% (88/126) of the articles related to projects granted by CIRP/PAHO/TDR were published in journals that have as main scope tropical medicine, public health, and parasitology/entomology (data not shown), the Brazilian journal "Memorias do Instituto Oswaldo Cruz" being the one with the highest number of articles published. In a previous analysis of publications about Chagas disease [27], similar results were obtained.

In a previous bibliometric study of more than 850 articles and abstracts retrieved using the search term "triatomine," it was shown that only 13% of them dealt with control/surveillance interventions (search term: "Triatomin* AND control") [29], indicating that in general, and contrary to the expectations of most funding agencies, research efforts have little bearing on disease control. Using the same search criteria for the 1997–2008 period we found that 7.5% of the articles retrieved with the search term "Triatomin*") and 9.0% of those retrieved with "Triatomin* AND control" were derived from projects granted by CIRP/PAHO/TDR, representing a very high proportion of the papers retrieved.

In addition, our data show that 64% of the 73 projects funded by CIRP/PAHO/TDR responded to the research needs and were focused, as Table S1 summarizes, on issues such as the epidemiological study of the impact of the control measures, the updating of information on the incidence of infection in young age groups, the entomological study of nondomiciliated triatomines, the genetics of vector populations, the generation of information on possible emergence of insecticide resistance and the establishment of a network for monitoring the resistance of vectors to insecticides, the cost-effectiveness of control strategies, or the validation and standardization of PCR as a diagnostic test and a marker of treatment results.

The available information indicates that CIRP/PAHO/TDR has had not only an impact in the production of knowledge valuable for the control programmes, but also a pivotal role in creating a critical mass of researchers in Chagas disease at country level, with an average per project of 2.7 graduated and post-graduate students (n=107), 0.4 technical reports (n=17), 0.7 extension activities (n=27), and a high number of health technicians for carrying out the entomo-epidemiological surveillance with the participation of the community. Furthermore, the programme has supported training courses for researchers and capacity-building activities for the personnel of national control programmes and has promoted the collaboration between researchers and managers. Two workshops to standardize and validate cPCR [26] and qPCR as methods for Chagas disease diagnosis and surrogate markers of treatment results were also carried out (data not published). Networks of PIs working on surveillance of insecticides resistance as well as PCR have been created. In addition, the programme has supported research that generated the submission of patents related to chemical substances to be used as baits for trapping triatomines.

Most grantees reported being involved in other activities, including development of research proposals, teaching, supervision of doctoral and postdoctoral students, and serving in expert committees or as peer reviewers.

In 2005–2006, the structure and procedures of TDR were reviewed and restructured and a 2008–2013 plan including eleven business lines was established. The technical and scientific support for Chagas disease of CIRP/PAHO/TDR was included in this new plan, supporting the development and evaluation of improved and innovative vector control intervention such as community-based ecosystem management for the prevention of Chagas disease among other vector-borne diseases, the continuation of the initiative to standardize and validate molecular markers, the evaluation of treatment, as well as individual and or institutional capacity building at the country level. These initiatives are still in place and have already yielded and are still yielding evidence that will have an impact on practice for Chagas disease [30][37].

In conclusion, the results of this evaluation yield evidence supporting that CIRP/PAHO/TDR research on Chagas disease has supported research that generated valuable evidence for prevention and control of Chagas disease. Chagas control initiatives have achieved important reductions in the incidence of Chagas disease in many Latin American countries. However, there are still areas producing new cases by oral transmission [38], [39], by wild triatomines [40], in areas where the control activities have been not successful [41], and in areas with nondomiciliated transmission [42], with many challenges ahead for the prevention and control of Chagas disease. These challenges include the need for new and/or improved drugs, diagnostics tools, vector research, eco-epidemiological studies, and integrated and sustainable control strategies, among others. Some of these needs are part of the actual TDR and PAHO research agenda.

We agree with Hotez et al. [43] that Chagas disease demands imperative attention from health policy makers to prioritize and develop a comprehensive strategy for surveillance, prevention, and control, for which more research and financial support are needed, both being crucial to address the unfinished agenda.

Box 1. Key Learning Points

  • Chagas disease is a potentially life-threatening disease transmitted by triatomine bugs (Hemiptera: Reduviidae) that is caused by T. cruzi, a parasite that infects an estimated 10 million people worldwide.
  • Initiatives led by PAHO aiming at the control of vectorial and transfusional transmission have led to the interruption of the transmission of the parasite by T. infestans in many areas of the Southern Cone and Central America.
  • CIRP/PAHO/TDR has contributed to the control of Chagas disease by supporting research of knowledge gaps and priority needs and training activities for the scientific and nonscientific community.
  • The need of better diagnostic tools, including biomarkers for assessing treatment efficacy, and safe treatments, as well as the development of an integrated vector control strategy make a compelling case to complete the unfinished research agenda.
  • Funding and political will is needed to sustain this work and achieve success in the challenges ahead.

Box 2. Top 5 Papers

  1. Coura JR, Pinto Dias JC (2009) Epidemiology, control and surveillance of Chagas disease -100 years after its discovery. Mem Inst Oswaldo Cruz 104: 31–40.
  2. Morel CM (1999) Chagas disease, from discovery to control - and beyond: history, myths and lessons to take home. Mem Inst Oswaldo Cruz 94: 3–16.
  3. World Health Organization (2008) Chagas disease: control and elimination. Report of the Secretariat.
  4. Gürtler RE, Diotaiuti L, Kitron U (2008) Commentary: Chagas disease: 100 years since discovery and lessons for the future. Int J Epidemiol 37: 698–701.
  5. Abad-Franch F, Santos WS, Schofield JC (2010) Research needs for Chagas disease prevention. Acta Trop 115: 44–54.

Supporting Information

Table S1.

Examples of Chagas disease research funded by CIRP/PAHO/TDR and their impact for control.



We thank G. A. Schmunis, R. E. Gürtler, and R. Becerre for their helpful and critical comments about the manuscript, and K. Darling, S. Schlesinger, and L. Pestana Silva for assistance with the English revision.


  1. 1. Coura JR, Pinto Dias JC (2009) Epidemiology, control and surveillance of Chagas disease -100 years after its discovery. Mem Inst Oswaldo Cruz 104: 31–40.
  2. 2. Moncayo A, Silveira CA (2009) Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 104: 17–30.
  3. 3. Schofield CJ (2010) Elimination of Chagas disease an end in sight? Public Health Journal 21: 7.
  4. 4. World Health Organization (2010) Chagas disease (American trypanosomiasis) fact sheet (revised in June 2010). Wkly Epidemiol Rec 85: 334–336.
  5. 5. Schmunis GA, Yadon ZE (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115: 14–21.
  6. 6. Walsh JA (1986) Estimating the burden of illness in the tropics. In: Warren KS, Mahmoud AAF, editors. Tropical and geographical medicine. McGraw-Hill.
  7. 7. Morel CM (1999) Chagas disease, from discovery to control - and beyond: history, myths and lessons to take home. Mem Inst Oswaldo Cruz 94: 3–16.
  8. 8. Yamagata Y, Nakagawa J (2006) Control of Chagas disease. Adv Parasitol 61: 129–165.
  9. 9. Hashimoto K, Schofield CJ (2012) Elimination of Rhodnius prolixus in Central America. Parasit Vectors 5: 1756–3305.
  10. 10. World Health Organization (2008) Chagas disease: control and elimination. Report of the Secretariat
  11. 11. Special Programme for Research and Training in Tropical Disease (2007) Reporte del grupo de trabajo científico sobre la enfermedad de Chagas: 17–20 de abril de 2005, actualizado en julio de 2007, Buenos Aires, Argentina. Geneva: World Health Organization. 96 p.
  12. 12. Yadon ZE (2001) Chagas disease intervention development and implementation research: transfer to the WHO regional office for the Americas. TDRnews. Geneva: Special Programme for Research and Training in Tropical Disease- TDR. pp. 17.
  13. 13. Yadon ZE (2002) Chagas disease: intervention development and implementation research. TDRnews. Geneva: Special Programme for Research and Training in Tropical Disease. pp. 15.
  14. 14. Pereira JCR, Pires ML, Duarte PS, Paes AT, Okano V (1996) Introducing a method of research evaluation into a university: medical research at the University of São Paulo, Brazil. Res Eval 6: 37–42.
  15. 15. Rousseau R (1998) Indicadores bibliométricos e econométricos para a avaliação de instituições científicas. Ci Inf Brasília 27: 149–158.
  16. 16. Gürtler RE, Diotaiuti L, Kitron U (2008) Commentary: Chagas disease: 100 years since discovery and lessons for the future. Int J Epidemiol 37: 698–701.
  17. 17. Dias JC (2009) Elimination of Chagas disease transmission: perspectives. Mem Inst Oswaldo Cruz 104 Suppl 1: 41–45.
  18. 18. Grijalva MJ, Escalante L, Paredes RA, Costales JA, Padilla A, et al. (2003) Seroprevalence and risk factors for Trypanosoma cruzi infection in the Amazon region of Ecuador. Am J Trop Med Hyg 69: 380–385.
  19. 19. Picollo MI, Vassena C, Santo Orihuela P, Barrios S, Zaidemberg M, et al. (2005) High resistance to pyrethroid insecticides associated with ineffective field treatments in Triatoma infestans (Hemiptera: Reduviidae) from Northern Argentina. J Med Entomol 42: 637–642.
  20. 20. Gurevitz JM, Ceballos LA, Gaspe MS, Alvarado-Otegui JA, Enríquez GF, et al. (2011) Factors affecting infestation by Triatoma infestans in a rural area of the humid Chaco in Argentina: a multi-model inference approach. PLoS Negl Trop Dis 5: e1349
  21. 21. Aguilar HM, Abad-Franch F, Dias JC, Junqueira AC, Coura JR (2007) Chagas disease in the Amazon region. Mem Inst Oswaldo Cruz 102 Suppl 1: 47–56.
  22. 22. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, et al. (2008) Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 37–43.
  23. 23. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, et al. (2009) The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104: 319–324.
  24. 24. Ponce C, Ponce E, Vinelli E, Montoya A, de Aguilar V, et al. (2005) Validation of a rapid and reliable test for diagnosis of chagas' disease by detection of Trypanosoma cruzi-specific antibodies in blood of donors and patients in Central America. J Clin Microbiol 43: 5065–5068.
  25. 25. Moreira OC, Ramirez JD, Velazquez E, Melo MF, Lima-Ferreira C, et al. (2013) Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial. Acta Trop 125: 23–31.
  26. 26. Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, et al. (2011) International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 5: e931
  27. 27. Ramos JM, González-Alcaide G, Gascón J, Gutiérrez F (2011) Mapping of Chagas disease research: analysis of publications in the period between 1940 and 2009. Rev Soc Bras Med Tropical 44: 708–716.
  28. 28. González-Alcaide G, Park J, Huamaní C, Gascón J, Ramos JM (2012) Scientific authorships and collaboration network analysis on Chagas disease: papers indexed in PubMed (1940–2009). Rev Inst Med Trop Sao Paulo 54: 219–228.
  29. 29. Abad-Franch F, Santos WS, Schofield JC (2010) Research needs for Chagas disease prevention. Acta Trop 115: 44–54.
  30. 30. Vazquez-Prokopec GM, Spillmann C, Zaidenberg M, Gürtler RE, Kitron U (2012) Spatial heterogeneity and risk maps of community infestation by Triatoma infestans in rural northwestern Argentina. PLoS Negl Trop Dis 6: e1788
  31. 31. Maffey L, Cardinal MV, Ordonez-Krasnowski PC, Lanati LA, Lauricella MA, et al. (2012) Direct molecular identification of Trypanosoma cruzi discrete typing units in domestic and peridomestic Triatoma infestans and Triatoma sordida from the Argentine Chaco. Parasitology 139: 1570–1579.
  32. 32. Alvarado-Otegui JA, Ceballos LA, Orozco MM, Enriquez GF, Cardinal MV, et al. (2012) The sylvatic transmission cycle of Trypanosoma cruzi in a rural area in the humid Chaco of Argentina. Acta Trop 124: 79–86.
  33. 33. Ceballos LA, Piccinali RV, Marcet PL, Vazquez-Prokopec GM, Cardinal MV, et al. (2012) Hidden sylvatic foci of the main vector of Chagas disease Triatoma infestans: threats to the vector elimination campaign? PLoS Negl Trop Dis 5: e1365
  34. 34. Enriquez GF, Cardinal MV, Orozco MM, Lanati L, Schijman AG, et al. (2012) Discrete typing units of Trypanosoma cruzi identified in rural dogs and cats in the humid Argentinean Chaco. Parasitology 12: 1–6.
  35. 35. Gaspe MS, Schachter-Broide J, Gurevitz J, Kitron U, Gürtler RE, et al. (2012) Microgeographic spatial structuring of Triatoma infestans (Hemiptera: Reduviidae) populations using wing geometric morphometry in the Argentine Chaco. J Med Entomol 49: 504–514.
  36. 36. Gurevitz JM, Gaspe MS, Enríquez GF, Vassena CV, Alvarado-Otegui JA, et al. (2012) Unexpected failures to control Chagas Disease vectors with pyrethroid spraying in northern Argentina. J Med Entomol 49: 1379–1386.
  37. 37. Duffy T, Cura CI, Ramirez JC, Abate T, Cayo NM, et al. (2013) Analytical performance of a multiplex real-time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS Negl Trop Dis 7: e2000
  38. 38. Shikanai-Yasuda MA, Carvalho NB (2012) Oral transmission of Chagas disease. Clin Infect Dis 54: 845–852.
  39. 39. Rios JF, Arboleda M, Montoya AN, Alarcon EP (2011) [Probable outbreak of oral transmission of Chagas disease in Turbo, Antioquia]. Biomedica 31: 185–195.
  40. 40. Guhl F, Pinto N, Aguilera G (2009) Sylvatic triatominae: a new challenge in vector control transmission. Mem Inst Oswaldo Cruz 1: 71–75.
  41. 41. Gurtler RE, Kitron U, Cecere MC, Segura EL, Cohen JE (2007) Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci U S A 104: 16194–16199.
  42. 42. Coura JR, Borges-Pereira J (2012) Chagas disease. What is known and what should be improved: a systemic review. Rev Soc Bras Med Trop 45: 286–296.
  43. 43. Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa JA, Bezek S, et al. (2012) Chagas disease: "the new HIV/AIDS of the Americas". PLoS Negl Trop Dis 6: e1498